Rubella (German Measles) - Pipeline Review, H2 2017

  • ID: 4426914
  • Report
  • Region: Germany
  • 33 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • Cadila Healthcare Ltd
  • Daiichi Sankyo Co Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Sinovac Biotech Ltd
  • MORE
Rubella (German Measles) - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Rubella (German Measles) - Pipeline Review, H2 2017, provides an overview of the Rubella (German Measles) (Infectious Disease) pipeline landscape.

Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 1, 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Rubella (German Measles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • Cadila Healthcare Ltd
  • Daiichi Sankyo Co Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Sinovac Biotech Ltd
  • MORE
Introduction

Rubella (German Measles) - Overview

Rubella (German Measles) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rubella (German Measles) - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Rubella (German Measles) - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

Cadila Healthcare Ltd

Daiichi Sankyo Co Ltd

GlaxoSmithKline Plc

Indian Immunologicals Ltd

Sinovac Biotech Ltd

Rubella (German Measles) - Drug Profiles

(measles + mumps + rubella + varicella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella + varicella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rubella vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VN-0102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rubella (German Measles) - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Rubella (German Measles), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017

Rubella (German Measles) - Pipeline by Biological E Ltd, H2 2017

Rubella (German Measles) - Pipeline by Cadila Healthcare Ltd, H2 2017

Rubella (German Measles) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Rubella (German Measles) - Pipeline by GlaxoSmithKline Plc, H2 2017

Rubella (German Measles) - Pipeline by Indian Immunologicals Ltd, H2 2017

Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd, H2 2017

Rubella (German Measles) - Dormant Projects, H2 2017

List of Figures

Number of Products under Development for Rubella (German Measles), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Minhai Biotechnology Co Ltd
  • Biological E Ltd
  • Cadila Healthcare Ltd
  • Daiichi Sankyo Co Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Sinovac Biotech Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll